Axonics Modular Technologies

Novel sacral neuromodulation system for treating overactive bladder

Axonics has developed a novel and potentially best-in-class implantable sacral neuromodulation (SNM) system for the treatment of overactive bladder and faecal incontinence.

It will be the smallest fully implantable, and first rechargeable SNM device, and is expected to work in the body for up to 15 years.

CEO  Raymond Cohen

www.axonics.com

Advent Contact  Shahzad Malik

Advent invested in the Series B in 2015.
Exited Investments
26 May 2022 in Advent Life Sciences, Press Release

Advent Life Sciences Announces Growth of Investment Team with Three Senior Appointments

Press Release.   26 May 2022, London, UK: Advent Life Sciences, a leading transatlantic venture and growth investor focused on building innovative life science companies in the UK, Europe, and…
Read More
17 March 2021 in Advent Life Sciences, Press Release

Advent Life Sciences’ founded Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets

Press Release.   This investment will fund Amphista Therapeutics’  growing pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and extend its proprietary platform. London, UK,…
Read More
12 March 2021 in Advent Life Sciences, Press Release

Advent Life Sciences Becomes Latest Partner of One Nucleus

Press Release.   Cambridge and London UK: 12th March 2021 Advent Life Sciences, one of the sector’s leading Trans-Atlantic venture investors has become the latest Partner to join One Nucleus.…
Read More
18 February 2021 in Advent Life Sciences, Press Release

Advent Life Sciences Announces Close of Two New Funds Totalling $215 million

Press Release.   18 February 2021, London, UK: Advent Life Sciences, a leading transatlantic venture investor focused on building innovative life science companies in the UK, Europe and the US,…
Read More